Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study
Standard
Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study. / Brinkmann, Christina; Abdel-Wahab, Mohamed; Bedogni, Francesco; Bhadra, Oliver D; Charbonnier, Gaetan; Conradi, Lenard; Hildick-Smith, David; Kargoli, Faraj; Latib, Azeem; Van Mieghem, Nicolas M; Miura, Mizuki; Mylotte, Darren; Landes, Uri; Pilgrim, Thomas; Riess, Friedrich-Christian; Taramasso, Maurizio; Tchétché, Didier; Testa, Luca; Thiele, Holger; Webb, John; Windecker, Stephan; Witt, Julian; Wohlmuth, Peter; Wolf, Alexander; Schofer, Joachim.
in: CATHETER CARDIO INTE, Jahrgang 98, Nr. 4, 10.2021, S. 756-764.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study
AU - Brinkmann, Christina
AU - Abdel-Wahab, Mohamed
AU - Bedogni, Francesco
AU - Bhadra, Oliver D
AU - Charbonnier, Gaetan
AU - Conradi, Lenard
AU - Hildick-Smith, David
AU - Kargoli, Faraj
AU - Latib, Azeem
AU - Van Mieghem, Nicolas M
AU - Miura, Mizuki
AU - Mylotte, Darren
AU - Landes, Uri
AU - Pilgrim, Thomas
AU - Riess, Friedrich-Christian
AU - Taramasso, Maurizio
AU - Tchétché, Didier
AU - Testa, Luca
AU - Thiele, Holger
AU - Webb, John
AU - Windecker, Stephan
AU - Witt, Julian
AU - Wohlmuth, Peter
AU - Wolf, Alexander
AU - Schofer, Joachim
N1 - © 2021 Wiley Periodicals LLC.
PY - 2021/10
Y1 - 2021/10
N2 - OBJECTIVES: To evaluate outcome and its predictors of bioprosthetic valve fracture (BVF) in patients undergoing valve-in-valve transcatheter aortic valve replacement (VIV-TAVR).BACKGROUND: BVF is feasible and reduces transvalvular gradients in VIV-TAVR-procedures, but follow-up-data and information on factors influencing the outcome are missing.METHODS: The 81 cases of BVF-VIV-TAVR were collected from 14 international centers.RESULTS: Predominantly transcatheter heart valve (THV) was implanted first, followed by BVF. VARC-2 defined device success was 93%, most failures were attributed to residual high gradients. Mean gradients decreased from 37 ± 13 mmHg to 10.8 ± 5.9 mmHg (p < 0.001). BVF reduced the gradient by 16 mmHg. During follow-up (FU, 281 ± 164 days) mean gradient remained stable (10.8 ± 5.9 mmHg at discharge, 12.4 ± 6.3 mmHg at FU, p = ns). In-hospital major adverse events occurred in 3.7%. Event-free survival at 276 ± 237.6 days was 95.4%. The linear mixed model identified balloon-expandable valves (BEV), Mitroflow surgical valve, stenotic surgical bioprostheses and balloon only 1 mm larger than the true internal diameter of the surgical valve as predictors for higher gradients.CONCLUSIONS: BVF is safe and can significantly reduce gradients, which remain stable at FU. BEV, Mitroflow surgical valve, stenotic bioprostheses and balloon larger than the true internal diameter of the surgical valve of only 1 mm are predictors for higher final gradients.
AB - OBJECTIVES: To evaluate outcome and its predictors of bioprosthetic valve fracture (BVF) in patients undergoing valve-in-valve transcatheter aortic valve replacement (VIV-TAVR).BACKGROUND: BVF is feasible and reduces transvalvular gradients in VIV-TAVR-procedures, but follow-up-data and information on factors influencing the outcome are missing.METHODS: The 81 cases of BVF-VIV-TAVR were collected from 14 international centers.RESULTS: Predominantly transcatheter heart valve (THV) was implanted first, followed by BVF. VARC-2 defined device success was 93%, most failures were attributed to residual high gradients. Mean gradients decreased from 37 ± 13 mmHg to 10.8 ± 5.9 mmHg (p < 0.001). BVF reduced the gradient by 16 mmHg. During follow-up (FU, 281 ± 164 days) mean gradient remained stable (10.8 ± 5.9 mmHg at discharge, 12.4 ± 6.3 mmHg at FU, p = ns). In-hospital major adverse events occurred in 3.7%. Event-free survival at 276 ± 237.6 days was 95.4%. The linear mixed model identified balloon-expandable valves (BEV), Mitroflow surgical valve, stenotic surgical bioprostheses and balloon only 1 mm larger than the true internal diameter of the surgical valve as predictors for higher gradients.CONCLUSIONS: BVF is safe and can significantly reduce gradients, which remain stable at FU. BEV, Mitroflow surgical valve, stenotic bioprostheses and balloon larger than the true internal diameter of the surgical valve of only 1 mm are predictors for higher final gradients.
KW - Aortic Valve/diagnostic imaging
KW - Aortic Valve Stenosis/diagnostic imaging
KW - Bioprosthesis
KW - Follow-Up Studies
KW - Heart Valve Prosthesis
KW - Hemodynamics
KW - Humans
KW - Prosthesis Design
KW - Prosthesis Failure
KW - Transcatheter Aortic Valve Replacement/adverse effects
KW - Treatment Outcome
U2 - 10.1002/ccd.29755
DO - 10.1002/ccd.29755
M3 - SCORING: Journal article
C2 - 33991385
VL - 98
SP - 756
EP - 764
JO - CATHETER CARDIO INTE
JF - CATHETER CARDIO INTE
SN - 1522-1946
IS - 4
ER -